LabCorp Furthers Leadership in Personalized Medicine in Cancer by Offering Innovative VistaSeq® Hereditary Cancer Panel
August 24 2015 - 8:45AM
Business Wire
VistaSeq strategically focuses on actionable
genetic mutations to identify patients with increased risk of many
commonly diagnosed cancers
Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:
LH) announced today the nationwide availability of its VistaSeq
Hereditary Cancer Panel, a novel, 27-gene panel designed to
identify patients with increased risk of breast, ovarian, melanoma,
pancreatic, colorectal, endometrial, gastric, prostate, and other
cancers. These cancers are projected to result in approximately
900,000 new diagnoses of cancer, and almost 200,000 deaths,
annually in the U.S.
“This innovative new offering enhances our industry-leading
portfolio of genetic and genomic testing, which we seamlessly
integrate with the largest cohort of board-certified genetic
counselors in the industry,” said David P. King, Chairman and Chief
Executive Officer. “VistaSeq is an important advancement in
precision medicine, and represents the latest example of our
strategic focus on delivering world-class diagnostics and using the
resulting information to change the way care is provided.”
The VistaSeq Hereditary Cancer Panel provides an assessment of
genetic mutations within a panel of 27 genes known to be associated
with hereditary cancer syndromes. The information provided is used
to determine an increased cancer risk in patients with an
associated personal or family history. Mutations in different genes
may cause the same type of cancer; conversely, one gene may be
associated with multiple hereditary cancer syndromes. VistaSeq will
give healthcare providers and patients additional information to
assist in understanding further monitoring and appropriate medical
management options.
NCCN Guidelines® and The Society of Gynecologic Oncology (SGO)
note that hereditary multi-gene panels may be an efficient and
cost–effective approach to genetic cancer testing when used in
appropriate clinical settings.
“LabCorp’s VistaSeq testing capabilities and services provide
physicians and patients with powerful tools for the assessment of
hereditary cancers," stated Dr. Marcia Eisenberg, LabCorp
Diagnostics’ Chief Scientific Officer. “VistaSeq was developed
based on our strong in-house expertise in genomics and the latest
advancements in science. LabCorp is a leader in genetic testing and
counseling services, and we continue to expand our innovative menu
of focused genetic tests.”
The VistaSeq test is available nationwide through any LabCorp
account, and will be performed by Integrated Genetics, a member of
LabCorp’s Specialty Testing Group. In addition, LabCorp offers a
complete range of complementary services to the testing for
patients and physicians, including insurance pre-authorization
support and access to genetic counselors, who are professionally
trained to analyze, assess, and interpret genetic test results.
About LabCorp®
Laboratory Corporation of America® Holdings, an S&P 500
company, is the world’s leading healthcare diagnostics company,
providing comprehensive clinical laboratory services through
LabCorp Diagnostics, and end-to-end drug development support
through Covance Drug Development. LabCorp is a pioneer in
commercializing new diagnostic technologies and is improving
people’s health by delivering the combination of world-class
diagnostics, drug development and knowledge services. With combined
revenue pro forma for the acquisition of Covance in excess of $8.5
billion in 2014 and more than 48,000 employees in over 60
countries, LabCorp offers innovative solutions to healthcare
stakeholders. LabCorp clients include physicians, patients and
consumers, biopharmaceutical companies, government agencies,
managed care organizations, hospitals, and clinical labs. To learn
more about Covance Drug Development, visit www.covance.com. To
learn more about LabCorp and LabCorp Diagnostics, visit
www.labcorp.com.
This press release contains forward-looking statements including
with respect to estimated 2015 guidance and the impact of various
factors on operating results. Each of the forward-looking
statements is subject to change based on various important factors,
including without limitation, competitive actions in the
marketplace, adverse actions of governmental and other third-party
payers and the results from the Company’s acquisition of Covance.
Actual results could differ materially from those suggested by
these forward-looking statements. Further information on potential
factors that could affect LabCorp’s operating and financial results
is included in the Company’s Form 10-K for the year ended December
31, 2014, and the Company’s Form 10-Q for the quarter ended June
30, 2015, including in each case under the heading risk factors,
and in the Company’s other filings with the SEC, as well as in the
risk factors included in Covance’s filings with the SEC. The
information in this press release should be read in conjunction
with a review of the Company’s filings with the SEC including the
information in the Company’s Form 10-K for the year ended December
31, 2014, and subsequent Forms 10-Q, under the heading MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150824005158/en/
LabCorp®Investor/Media Contact:Paul Surdez,
336-436-5076Company Information: www.labcorp.com
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024